Genome-wide DNA methylation status is a predictor of the efficacy of anti-EGFR antibodies in the second-line treatment of metastatic colorectal cancer: Translational research of the EPIC trial

Ouchi, Kota, Takahashi, Shin, Sasaki, Keiju, Yoshida, Yuya, Taniguchi, Sakura, Kasahara, Yuki, Komine, Keigo, Imai, Hiroo, Saijo, Ken, Shirota, Hidekazu, Takahashi, Masanobu, Ishioka, Chikashi

International Journal of Colorectal Disease: Clinical and Molecular Gastroenterology and Surgery. 39(1)